Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Selvaggi

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
BMC Cancer|July 10, 2015
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancerDevalingam Mahalingam, Sukeshi Patel, Gerard Nuovo, et al.
Frontiers in Oncology|November 25, 2021
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-AnalysisLing Peng, Dafeng Lu, Yang Xia, et al.
Clinical Lung Cancer|June 28, 2006
Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancerPaulo Ghio, Susanna Cappia, Giovanni Selvaggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancerDaniela F Giachino, Paolo Ghio, Silvia Regazzoni, et al.
Oncotargets and Therapy|June 3, 2021
Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLCLing Peng, Kui Xiao, Jian Cui, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2017
A phase II study of REOLYSIN<sup>®</sup> (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanomaDevalingam Mahalingam, Christos Fountzilas, Jennifer Moseley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapyLuisella Righi, Mauro G Papotti, Paolo Ceppi, et al.
Cancer|August 14, 2002
HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survivalGiovanni Selvaggi, Giorgio V Scagliotti, Valter Torri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective studyPaolo Ceppi, Marina Longo, Marco Volante, et al.
JTO Clinical and Research Reports|November 19, 2025
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and OutcomesSurbhi Singhal, Caressa Hui, Joel W Neal, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
BMC Cancer|July 10, 2015
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancerDevalingam Mahalingam, Sukeshi Patel, Gerard Nuovo, et al.
Frontiers in Oncology|November 25, 2021
Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-AnalysisLing Peng, Dafeng Lu, Yang Xia, et al.
Clinical Lung Cancer|June 28, 2006
Prognostic role of protease-activated receptors 1 and 4 in resected stage IB non-small-cell lung cancerPaulo Ghio, Susanna Cappia, Giovanni Selvaggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2007
Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancerDaniela F Giachino, Paolo Ghio, Silvia Regazzoni, et al.
Oncotargets and Therapy|June 3, 2021
Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLCLing Peng, Kui Xiao, Jian Cui, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2017
A phase II study of REOLYSIN<sup>®</sup> (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanomaDevalingam Mahalingam, Christos Fountzilas, Jennifer Moseley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapyLuisella Righi, Mauro G Papotti, Paolo Ceppi, et al.
Cancer|August 14, 2002
HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survivalGiovanni Selvaggi, Giorgio V Scagliotti, Valter Torri, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2008
Excision repair cross complementing-1 and topoisomerase IIalpha gene expression in small-cell lung cancer patients treated with platinum and etoposide: a retrospective studyPaolo Ceppi, Marina Longo, Marco Volante, et al.
JTO Clinical and Research Reports|November 19, 2025
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and OutcomesSurbhi Singhal, Caressa Hui, Joel W Neal, et al.
Pageof 4